FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Search
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Cardio-Renal-Metabolic
Cardio-Renal-Metabolic Therapeutic Area
Life stages of cats
Cats go through different stages of life. Knowing more about these stages can help you understand your cat’s medical needs better.
Generalized pustular psoriasis is not ‘sensitive’ content
Learn about the impact that a lack of online visibility can have on people living with this chronic, inflammatory skin disease.
Genomic Lens Linking Worlds in DNA
Adding a new dimension to drug discovery with the help of data science and DNA
Berotec®
Symptomatic treatment of acute asthma attacks. Prophylaxis of exercise-induced asthma bronchiale. Symptomatic treatment of allergic and non-allergic asthma bronchiale and other conditions with reversible airway narrowing, e.g. chronic obstructive bro
Future of Diabetes
This video highlights the evolution of type 2 diabetes management
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.